This clinical trial is focused on studying the prevention of migraine, a common type of headache that can cause severe pain, nausea, and sensitivity to light and sound. The study will test a new treatment called Lu AG09222, which is given as a solution for injection. Participants in the trial will receive either the new treatment or a placebo, which is a substance with no active medication, to compare the effects.
The purpose of the study is to evaluate how effective Lu AG09222 is in preventing migraines in adults who have not found relief from previous preventive treatments. The study will involve participants with both episodic and chronic forms of migraine. During the trial, participants will be randomly assigned to different groups, and neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure that the results are unbiased.
Participants will be monitored over a period of time to track changes in their migraine frequency and severity. The study will also assess the safety of Lu AG09222 by checking for any side effects and changes in health indicators such as vital signs and laboratory test results. The trial aims to provide valuable information on whether this new treatment can offer a new option for people suffering from migraines.
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Hungary 
Lithuania 
Poland 
Romania 
Slovakia 
Spain 
